Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)‐TIMI 53 trial
Year: 2013
Type: article
DOI: 10.1002/dmrr.2413
Institutions: Hadassah Medical Center, Brigham and Women's Hospital, Harvard University, Thrombolysis in Myocardial Infarction Study Group, AstraZeneca (United States), AstraZeneca (Sweden), Inserm, Sorbonne Paris Cité, Université Paris Diderot, The University of Texas Southwestern Medical Center, Bristol-Myers Squibb (United States), VA Boston Healthcare System
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Keywords: saxagliptin, SAVOR-TIMI 53, type 2 diabetes, DPP-4 inhibitors, cardiovascular outcomes, baseline characteristics, HbA1c, diabetes treatment, insulin use, statin use, diabetes complications, diabetic nephropathy, diabetic retinopathy, microalbuminuria, inflammatory markers, insulin resistance, regional variation
Open Access status: closed
OpenAlex ID: W1494561942
